Yazeed Sawalha, MD, on How Socioeconomic Factors May Impact Completion of ASCT and Clinical Outcomes in MCL

News
Article

Yazeed Sawalha, MD, discusses how socioeconomic factors may impact the completion of autologous stem cell transplant in patients with mantle cell lymphoma, as well as impacting clinical outcomes.

CancerNetwork® spoke with Yazeed Sawalha, MD, a hematologist at the Ohio State University Comprehensive Cancer Center–The James, about the impact of certain socioeconomic factors on the completion of autologous stem cell transplant (ASCT) and clinical outcomes in patients with mantle cell lymphoma.

According to Sawalha, factors such as insurance type, treatment facility, and location were associated with chances of completing ASCT, and education and race impacted survival outcomes.

Transcript:

We looked at the impact of demographics and socioeconomic factors on the use of ASCT, but also on clinical outcomes—specifically overall survival. We found that after adjusting for other factors, the type of insurance and specifically having private insurance rather than Medicare, as well as receiving treatment at an academic or research facility, and certain geographical locations are actually associated with higher chances of undergoing ASCT.

In terms of clinical outcomes and survival, we found that the type of insurance was also important here. In addition, higher education and income levels were also associated with superior survival, whereas Black race was associated with inferior survival.

Reference

Sawalha Y, Radivoyevitch T, Jia X, et al. The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. Leukemia & Lymphoma. Published online September 15, 2021. doi:10.1080/10428194.2021.1978085

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Related Content